LPL Financial LLC Has $2.32 Million Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

LPL Financial LLC cut its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 11.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 49,882 shares of the company’s stock after selling 6,462 shares during the quarter. LPL Financial LLC owned about 0.08% of Twist Bioscience worth $2,318,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Barclays PLC raised its holdings in Twist Bioscience by 214.8% in the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after acquiring an additional 104,420 shares in the last quarter. Avanza Fonder AB acquired a new position in shares of Twist Bioscience in the fourth quarter valued at $1,059,000. Principal Financial Group Inc. lifted its position in Twist Bioscience by 67.5% in the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock worth $9,301,000 after purchasing an additional 82,953 shares during the period. Oddo BHF Asset Management Sas acquired a new stake in Twist Bioscience during the third quarter worth $3,302,000. Finally, KBC Group NV increased its holdings in Twist Bioscience by 71.4% in the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock valued at $137,000 after buying an additional 1,226 shares during the period.

Insider Transactions at Twist Bioscience

In other news, COO Patrick John Finn sold 2,422 shares of the firm’s stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $50.17, for a total transaction of $121,511.74. Following the completion of the sale, the chief operating officer now owns 272,044 shares of the company’s stock, valued at $13,648,447.48. This trade represents a 0.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Robert Chess sold 2,940 shares of the business’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $53.13, for a total transaction of $156,202.20. Following the transaction, the director now owns 18,173 shares in the company, valued at $965,531.49. The trade was a 13.93 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,796 shares of company stock worth $1,077,383. Company insiders own 3.01% of the company’s stock.

Twist Bioscience Stock Up 2.5 %

Shares of TWST opened at $39.82 on Tuesday. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The firm’s 50 day moving average is $41.55 and its 200-day moving average is $44.60. The stock has a market capitalization of $2.38 billion, a PE ratio of -11.78 and a beta of 2.34.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company’s revenue was up 24.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.75) earnings per share. Equities research analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on TWST shares. Robert W. Baird increased their target price on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Barclays cut their price objective on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. Guggenheim set a $50.00 target price on shares of Twist Bioscience in a report on Friday, March 28th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $52.80.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.